PIM-1 kinase inhibitor SMI-4a exerts antitumor effects in chronic myeloid leukemia cells by enhancing the activity of glycogen synthase kinase 3β. [electronic resource]
Producer: 20180521Description: 4603-4612 p. digitalISSN:- 1791-3004
- Antineoplastic Agents -- pharmacology
- Apoptosis -- drug effects
- Benzylidene Compounds -- pharmacology
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Cell Survival -- drug effects
- Glycogen Synthase Kinase 3 beta -- metabolism
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Protein Kinase Inhibitors -- pharmacology
- Protein Transport
- Proto-Oncogene Proteins c-pim-1 -- antagonists & inhibitors
- Thiazolidinediones -- pharmacology
- beta Catenin -- metabolism
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.